24 Apr 2025 · 1 min read
Biolinq raises $100M to disrupt glucose monitoring - but what makes their patch different?
Biolinq has raised $100M to challenge the CGM market with an intradermal patch that uses microneedles and a built-in LED display — and I break down what makes their approach genuinely different from devices like Abbott's FreeStyle Libre.